Role of PCSK9 Inhibitors in Diabetes

Stephen Kopecky

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

National Lipid Association

R. Mason

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

Colchicine: Now and What’s Next?

National Lipid Association

C. Ballantyne

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Practical Ways to Achieve Targets in Diabetes Care

S. Nissen

Plant-based Diets for Improving Lipids

National Lipid Association

K. Williams

Role of Lipoprotein (a) in Coronary Disease: An Emerging Novel Target

Practical Ways to Achieve Targets in Diabetes Care

S. Nissen

State-of-the-Art, Treatment of Diabetic Kidney Disease (DKD)

Primary Care Education Consortium

S. Brunton

Aspirin for the Primary Prevention of Cardiovascular Disease: What C…

Houston Methodist DeBakey Heart and Vascular Center

M. Miedema

Current Status of Prevention and Treatment of Diabetic Nephropathy

George Bakris

Patients in Cardiometabolic Jeopardy: Evolving Strategies for Cardio…

MUSC Cardiology

D. Lloyd-Jones

Use of Finerenone in Patients with Diabetes Who Have Kidney Disease

The Texas Heart Institute

G. Bakris

What's the Ideal Therapy for Obesity?

Stanford Medicine

A. Yeoh

New Medications for Heart Failure: SGLT2 Inhibitors and Vericiguat. …

American Heart & Vascular Institute

M. Kittleson

ACC 2024 Insights: Evolving Pharmacology for HFrEF vs. HFpFF - With …

ACC 2024 Insights

M. Costanzo

SGLT2 Inhibitors and Heart Failure in Type-2 Diabetes Mellitus

Javed Butler

Management of Kidney Health in CKD and DKD: A Cased-Based Multiple-c…

Bijin Thajudeen

Diabetes and Heart Failure: The New Frontier

Mount Sinai Advanced Innovations in Heart Failure Symposium 2019

E. Braunwald